Abbvie 3Q Revenues: $15.8 billion (+9%)  3Q Earnings: $186 million (earnings were $1.6B 3Q24) YTD Revenues: $44.5 billion (+8%) YTD Earnings: $2.4 billion (-44%) Comments: Global sales from the immunology portfolio were $7.9 billion, up 12%. Skyrizi sales were $4.7 billion, up 47%. Rinvoq sales were $2.2 billion, up 35%. Humira sales were $993 million, down 55%. Global revenues from the oncology portfolio were flat at $1.7 billion. Imbruvica sales were $706 milli...